{"id":60137,"date":"2024-02-28T06:35:09","date_gmt":"2024-02-28T06:35:09","guid":{"rendered":"https:\/\/medsname.com\/psyquit\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"psyquit","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/psyquit\/","title":{"rendered":"Psyquit"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Psyquit?<\/h3>\n
\n

Psyquit<\/strong> obsahuje quetiapin 25 \/ 100 \/ 200 mg (s okam\u017eit\u00fdm uvoln\u011bn\u00edm)<\/strong> od v\u00fdrobce s certifikac\u00ed WHO-GMP (Sun Pharma) \u2014 atypick\u00fdch antipsychotik<\/strong> s \u0161irok\u00fdm pou\u017eit\u00edm u schizofrenie, bipol\u00e1rn\u00ed poruchy a l\u00e9\u010debn\u011b rezistentn\u00ed deprese. Mechanismus: D2 + 5-HT2A<\/sub> antagonismus plus v\u00fdrazn\u00e9 H1<\/sub> antihistaminov\u00fd \u00fa\u010dinek (siln\u00e1 sedace) plus blok\u00e1da alfa-1 (ortostatick\u00e1 hypotenze). D\u00e1vkov\u00e1n\u00ed se v\u00fdrazn\u011b li\u0161\u00ed podle indikace: 25\u2013100 mg HS<\/strong> (off-label nespavost, anxiolytick\u00e1 adjuvans \u2014 kontroverzn\u00ed), 300\u2013800 mg\/den<\/strong> (schizofrenie, bipol\u00e1rn\u00ed m\u00e1nie), 150\u2013300 mg\/den<\/strong> (bipol\u00e1rn\u00ed deprese, adjuvans u MDD). Hlavn\u00ed varov\u00e1n\u00ed t\u0159\u00eddy<\/strong>: metabolick\u00fd syndrom (v\u00e1ha, gluk\u00f3za, lipidy \u2014 t\u0159\u00eddn\u00ed \u00fa\u010dinek), siln\u00e1 sedace, ortostatick\u00e1 hypotenze, prodlou\u017een\u00ed QT intervalu, EPS (m\u00e9n\u011b ne\u017e u antipsychotik prvn\u00ed generace) a FDA \u010dern\u00e9 varov\u00e1n\u00ed pro mortalitu u star\u0161\u00edch pacient\u016f s demenc\u00ed<\/strong>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Psyquit je atypick\u00fdch antipsychotik<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro schizofrenie, bipol\u00e1rn\u00ed m\u00e1nie a deprese, udr\u017eovac\u00ed l\u00e9\u010dba bipol\u00e1rn\u00ed poruchy a adjuvans u l\u00e9\u010dby velk\u00e9 depresivn\u00ed poruchy<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 mortalita u star\u0161\u00edch pacient\u016f s demenc\u00ed.<\/strong> V\u0161echna antipsychotika (atypick\u00e1 i konven\u010dn\u00ed) nesou FDA \u010dern\u00e9 varov\u00e1n\u00ed pro zv\u00fd\u0161enou mortalitu p\u0159i l\u00e9\u010db\u011b psych\u00f3zy nebo behavior\u00e1ln\u00edch poruch souvisej\u00edc\u00edch s demenc\u00ed u star\u0161\u00edch pacient\u016f. Tento l\u00e9k je FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> pro p\u0159\u00edznaky spojen\u00e9 s demenc\u00ed.<\/div>\n

Co je Psyquit?<\/h2>\n

Psyquit je peror\u00e1ln\u00ed tableta s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm quetiapin fumar\u00e1t 25\/100\/200 mg<\/strong> vyr\u00e1b\u011bn\u00e1 spole\u010dnost\u00ed Sun Pharma. Quetiapin (americk\u00e1 zna\u010dka Seroquel IR\/Seroquel XR<\/strong>) je atypick\u00e9 (druh\u00e9 generace) antipsychotikum uveden\u00e9 na trh spole\u010dnost\u00ed AstraZeneca v roce 1997. Jedn\u00e1 se o D2<\/sub> a 5-HT2A<\/sub> antagonista se silnou H1<\/sub> antihistaminovou a st\u0159edn\u00ed alfa-1 antagonistickou aktivitou<\/strong>. H1<\/sub> blok\u00e1da zp\u016fsobuje v\u00fdraznou sedaci; blok\u00e1da alfa-1 vede k ortostatick\u00e9 hypotenzi; antagonismus 5-HT2A<\/sub> sni\u017euje riziko extrapyramidov\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f ve srovn\u00e1n\u00ed s antipsychotiky prvn\u00ed generace.<\/p>\n

The IR (s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm)<\/strong> forma dosahuje vrcholn\u00e9 plazmatick\u00e9 koncentrace za 1\u20132 hodiny, co\u017e zp\u016fsobuje rychlou sedaci. Na\u010dasov\u00e1n\u00ed d\u00e1vky je d\u016fle\u017eit\u00e9 \u2014 sedace 1\u20133 hodiny po pod\u00e1n\u00ed m\u016f\u017ee b\u00fdt u\u017eite\u010dn\u00e1 (p\u0159i nespavosti) nebo limituj\u00edc\u00ed (denn\u00ed \u00fanava).<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Schizofrenii<\/strong> \u2014 akutn\u00ed a udr\u017eovac\u00ed<\/li>\n
  • Bipol\u00e1rn\u00ed m\u00e1nie<\/strong> \u2014 akutn\u00ed (monoterapie nebo s lithiem\/valpro\u00e1tem)<\/li>\n
  • Bipol\u00e1rn\u00ed deprese<\/strong> \u2014 jeden z m\u00e1la l\u00e9k\u016f schv\u00e1len\u00fdch FDA pro tento \u00fa\u010del; prvn\u00ed volba u bipol\u00e1rn\u00ed deprese I<\/li>\n
  • Bipol\u00e1rn\u00ed udr\u017eovac\u00ed l\u00e9\u010dba<\/strong> \u2014 s lithiem nebo valpro\u00e1tem<\/li>\n
  • Pomocn\u00e1 l\u00e9\u010dba MDD<\/strong> \u2014 forma XR, 150\u2013300 mg\/den s antidepresivem<\/li>\n
  • Mimo indikaci: nespavost (n\u00edzk\u00e1 d\u00e1vka 25\u201350 mg), \u00fazkost (kontroverzn\u00ed \u2014 metabolick\u00e9 riziko u nepsychotick\u00e9 \u00fazkosti), agitace u demence (pou\u017e\u00edv\u00e1 se opatrn\u011b kv\u016fli \u010dern\u00e9 v\u00fdstraze)<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed podle indikace<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    Schizofrenie (IR)<\/td>\n50 mg 2\u00d7 denn\u011b<\/td>\n400\u2013800 mg\/den<\/td>\n800 mg\/den<\/td>\nTitrujte po dobu 4\u20137 dn\u016f; XR umo\u017e\u0148uje jednodenn\u00ed pod\u00e1n\u00ed p\u0159ed span\u00edm<\/td>\n<\/tr>\n
    Bipol\u00e1rn\u00ed m\u00e1nie (akutn\u00ed)<\/td>\n100 mg\/den \u00d7 den 1, zvy\u0161te o 100 mg\/den<\/td>\n400\u2013800 mg\/den<\/td>\n800 mg\/den<\/td>\nRychl\u00e1 titrace pro kontrolu m\u00e1nie<\/td>\n<\/tr>\n
    Bipol\u00e1rn\u00ed deprese<\/td>\n50 mg HS \u00d7 den 1, pot\u00e9 100, 200, 300<\/td>\n300 mg\/den p\u0159ed span\u00edm<\/td>\n300 mg\/den<\/td>\nStandardn\u00ed maximum pro tuto indikaci<\/td>\n<\/tr>\n
    P\u0159\u00eddavek k MDD (pouze XR)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n150\u2013300 mg\/den<\/td>\n300 mg\/den<\/td>\nP\u0159idat k st\u00e1vaj\u00edc\u00edmu antidepresivu; sedace \u010dasto limituje d\u00e1vkov\u00e1n\u00ed<\/td>\n<\/tr>\n
    Neschv\u00e1len\u00e9 pou\u017eit\u00ed p\u0159i nespavosti<\/td>\n25\u201350 mg HS<\/td>\n25\u201350 mg HS<\/td>\n100 mg HS<\/td>\nKontroverzn\u00ed \u2014 metabolick\u00e9 riziko spojen\u00e9 s d\u00e1vkou na span\u00ed z toho \u010din\u00ed \u0161patnou prvn\u00ed volbu; vyhrazeno pro pacienty, kte\u0159\u00ed selhali u v\u00edce alternativ<\/td>\n<\/tr>\n
    Star\u0161\u00ed pacienti<\/td>\n25\u201350 mg\/den, pomalej\u0161\u00ed titrace<\/td>\n\u2014<\/td>\nZva\u017ete maximum 200\u2013300 mg\/den<\/td>\nV\u011bt\u0161\u00ed sedace a ortostatick\u00e1 hypotenze \u2014 riziko p\u00e1d\u016f<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    Profil vedlej\u0161\u00edch \u00fa\u010dink\u016f podle mechanismu<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Mechanismus \u00fa\u010dinku<\/th>\n\u00da\u010dinky<\/th>\nPozn\u00e1mky \/ management<\/th>\n<\/tr>\n<\/thead>\n
    Metabolick\u00e9 (5-HT2C<\/sub> + H1<\/sub> chu\u0165 k j\u00eddlu)<\/td>\nP\u0159\u00edr\u016fstek hmotnosti (\u010dasto v\u00fdrazn\u00fd), zv\u00fd\u0161en\u00e1 hladina gluk\u00f3zy v krvi \/ nov\u011b vznikl\u00fd diabetes, dyslipid\u00e9mie<\/td>\nVarov\u00e1n\u00ed pro t\u0159\u00eddu \u2014 v\u00fdchoz\u00ed hmotnost, TK, glyk\u00e9mie nala\u010dno, lipidy; p\u0159ehodnocen\u00ed za 3 m\u011bs\u00edce a ro\u010dn\u011b<\/td>\n<\/tr>\n
    H1<\/sub> blok\u00e1da<\/td>\nSiln\u00e1 sedace, ospalost<\/td>\nU\u017eite\u010dn\u00e9 p\u0159ed span\u00edm; \u010dasto limituj\u00edc\u00ed b\u011bhem dne. M\u00e9n\u011b vrcholov\u00e9 sedace s XR<\/td>\n<\/tr>\n
    Blok\u00e1da alfa-1<\/td>\nOrtostatick\u00e1 hypotenze, z\u00e1vrat\u011b<\/td>\nPomal\u00e1 titrace; kontrola TK vle\u017ee \/ vestoje<\/td>\n<\/tr>\n
    Anticholinergn\u00ed \u00fa\u010dinek (m\u00edrn\u00fd)<\/td>\nSucho v \u00fastech, z\u00e1cpa<\/td>\nM\u00e9n\u011b ne\u017e olanzapin<\/td>\n<\/tr>\n
    D2<\/sub> blok\u00e1da<\/td>\nExtrapyramidov\u00e9 p\u0159\u00edznaky (akathisie, parkinsonismus, dystonie)<\/td>\nM\u00e9n\u011b ne\u017e antipsychotika prvn\u00ed generace; akathisie p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch<\/td>\n<\/tr>\n
    Jin\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nV\u00fdchoz\u00ed EKG; opatrnost s dal\u0161\u00edmi l\u00e9ky prodlu\u017euj\u00edc\u00edmi QT interval<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nTardivn\u00ed dyskineze<\/td>\nNi\u017e\u0161\u00ed riziko ne\u017e u typick\u00fdch antipsychotik, ale re\u00e1ln\u00e9 p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nNeuroleptick\u00fd malign\u00ed syndrom<\/td>\nHypertermie, rigidita, autonomn\u00ed nestabilita \u2014 nouzov\u00fd stav<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nHyperprolaktin\u00e9mie<\/td>\nM\u00e9n\u011b ne\u017e risperidon<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\n\u0160ed\u00fd z\u00e1kal<\/td>\nMonitorov\u00e1n\u00ed \u010do\u010dky je kontroverzn\u00ed; n\u011bkte\u0159\u00ed klinici na\u0159izuj\u00ed p\u016flro\u010dn\u00ed vy\u0161et\u0159en\u00ed \u0161t\u011brbinovou lampou<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    CYP3A4 substr\u00e1t<\/strong>: hladiny stoupaj\u00ed se siln\u00fdmi inhibitory (ketokonazol, ritonavir, klarithromycin) \u2014 sni\u017ete d\u00e1vku. Hladiny klesaj\u00ed se siln\u00fdmi induktory (rifampin, fenytoin, karbamazepin) \u2014 ztr\u00e1ta \u00fa\u010dinnosti.<\/p>\n

    Aditivn\u00ed sedace<\/strong>: alkohol, benzodiazepiny, opioidy, sedativn\u00ed antidepresiva.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu<\/strong>: opatrnost s citalopramem (vysok\u00e1 d\u00e1vka), methadonem, ondansetronem, fluorochinolony, ziprasidonem.<\/p>\n

    Antihypertenziva<\/strong>: aditivn\u00ed ortostatick\u00e1 hypotenze s alfa-blok\u00e1tory, ACE inhibitory, diuretiky.<\/p>\n

    Anticholinergn\u00ed z\u00e1t\u011b\u017e<\/strong>: aditivn\u00ed s difenhydraminem, oxybutyninem.<\/p>\n

    Metabolick\u00e9 monitorov\u00e1n\u00ed<\/h2>\n

    V\u0161echna atypick\u00e1 antipsychotika nesou t\u0159\u00eddn\u00ed varov\u00e1n\u00ed pro metabolick\u00fd syndrom \u2014 p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze, dyslipidemie a porucha gluk\u00f3zov\u00e9 tolerance. Kvetiapin pat\u0159\u00ed do skupiny s vy\u0161\u0161\u00edm rizikem (spolu s olanzapinem a klozapinem). Standardn\u00ed monitorov\u00e1n\u00ed: v\u00fdchoz\u00ed + 3 m\u011bs\u00edce + ro\u010dn\u011b<\/strong>: hmotnost \/ BMI, obvod pasu, hladina gluk\u00f3zy nala\u010dno nebo HbA1c, lipidov\u00fd panel nala\u010dno, krevn\u00ed tlak. Zva\u017ete p\u0159echod na l\u00e1tku s ni\u017e\u0161\u00edm metabolick\u00fdm rizikem (aripiprazol, lurasidon, ziprasidon), pokud se zhor\u0161\u00ed hmotnost \/ gluk\u00f3za.<\/p>\n

    \u010casto kladen\u00e9 dotazy<\/h2>\n

    Jak dlouho trv\u00e1, ne\u017e Psyquit za\u010dne \u00fa\u010dinkovat?<\/h3>\n

    Akutn\u00ed psych\u00f3za nebo p\u0159\u00edznaky m\u00e1nie \u010dasto reaguj\u00ed b\u011bhem dn\u016f; pln\u00fd \u00fa\u010dinek nast\u00e1v\u00e1 za 4\u20136 t\u00fddn\u016f. U bipol\u00e1rn\u00ed deprese se odpov\u011b\u010f obvykle objev\u00ed za 1\u20133 t\u00fddny p\u0159i c\u00edlov\u00e9 d\u00e1vce 300 mg.<\/p>\n

    Pro\u010d se Psyquit pou\u017e\u00edv\u00e1 na sp\u00e1nek?<\/h3>\n

    Quetiapin 25\u201350 mg HS zp\u016fsobuje silnou sedaci blok\u00e1dou H1<\/sub> receptor\u016f. Pou\u017eit\u00ed mimo indikaci pro sp\u00e1nek je roz\u0161\u00ed\u0159en\u00e9, ale kontroverzn\u00ed \u2014 metabolick\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky se hromad\u00ed i p\u0159i n\u00edzk\u00fdch d\u00e1vk\u00e1ch a existuj\u00ed bezpe\u010dn\u011bj\u0161\u00ed hypnotika.<\/p>\n

    Zp\u016fsob\u00ed Psyquit p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze?<\/h3>\n

    Pravd\u011bpodobn\u011b ano \u2014 quetiapin pat\u0159\u00ed mezi atypick\u00e1 antipsychotika s vy\u0161\u0161\u00edm rizikem p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze. Pr\u016fm\u011brn\u00fd p\u0159\u00edr\u016fstek hmotnosti p\u0159i terapeutick\u00fdch d\u00e1vk\u00e1ch je 4\u20137 kg za 12 m\u011bs\u00edc\u016f; n\u011bkte\u0159\u00ed pacienti p\u0159iberou v\u00fdrazn\u011b v\u00edce. Pom\u00e1haj\u00ed zm\u011bny \u017eivotn\u00edho stylu; p\u0159i probl\u00e9mov\u00e9m p\u0159ib\u00edr\u00e1n\u00ed m\u016f\u017ee b\u00fdt nutn\u00e9 p\u0159ej\u00edt na aripiprazol nebo lurasidon.<\/p>\n

    Je Psyquit bezpe\u010dn\u00fd pro star\u0161\u00ed pacienty s demenc\u00ed?<\/h3>\n

    FDA varuje \u010dern\u00fdm r\u00e1me\u010dkem o zv\u00fd\u0161en\u00e9 \u00famrtnosti u star\u0161\u00edch osob s psych\u00f3zou nebo behavior\u00e1ln\u00edmi poruchami souvisej\u00edc\u00edmi s demenc\u00ed. Pou\u017e\u00edvejte pouze tehdy, kdy\u017e behavior\u00e1ln\u00ed a nefarmakologick\u00e9 strategie selhaly a p\u0159\u00edznaky jsou z\u00e1va\u017en\u00e9; nejni\u017e\u0161\u00ed d\u00e1vka, nejkrat\u0161\u00ed doba, s informovan\u00fdm souhlasem rodiny.<\/p>\n

    M\u016f\u017eu p\u00edt alkohol p\u0159i u\u017e\u00edv\u00e1n\u00ed Psyquitu?<\/h3>\n

    Vyhn\u011bte se \u2014 doch\u00e1z\u00ed k aditivn\u00ed sedaci a ortostatick\u00e9 hypotenzi. I m\u00edrn\u00e9 mno\u017estv\u00ed alkoholu v\u00fdrazn\u011b zvy\u0161uje riziko sedace a p\u00e1d\u016f.<\/p>\n

    Jak\u00fd je rozd\u00edl mezi IR a XR quetiapinem?<\/h3>\n

    IR vrchol\u00ed za 1\u20132 hodiny; XR vrchol\u00ed za ~6 hodin a umo\u017e\u0148uje jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed. IR m\u00e1 v\u00fdrazn\u011bj\u0161\u00ed sedaci t\u011bsn\u011b po d\u00e1vce; XR m\u00e1 hlad\u0161\u00ed profil. Denn\u00ed AUC je podobn\u00e1 p\u0159i ekvivalentn\u00edch d\u00e1vk\u00e1ch.<\/p>\n

    Zp\u016fsob\u00ed Psyquit extrapyramidov\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n

    Quetiapin m\u00e1 spolu s klozapinem nejni\u017e\u0161\u00ed riziko EPS mezi atypick\u00fdmi antipsychotiky. Akatizie p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch je nej\u010dast\u011bj\u0161\u00edm motorick\u00fdm vedlej\u0161\u00edm \u00fa\u010dinkem; riziko tardivn\u00ed dyskineze existuje p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed, ale je mnohem ni\u017e\u0161\u00ed ne\u017e u antipsychotik prvn\u00ed generace.<\/p>\n

    Je Psyquit bezpe\u010dn\u00fd v t\u011bhotenstv\u00ed?<\/h3>\n

    Omezen\u00e1 data \u2014 kvetiapin pat\u0159\u00ed mezi l\u00e9pe prostudovan\u00e9 atypick\u00e9 antipsychotikum v t\u011bhotenstv\u00ed. Pokra\u010dov\u00e1n\u00ed v l\u00e9\u010db\u011b je rozumn\u00e9, je-li nutn\u00e9 pro z\u00e1va\u017en\u00e9 du\u0161evn\u00ed onemocn\u011bn\u00ed; expozice v prvn\u00edm trimestru nezv\u00fd\u0161\u00ed pravd\u011bpodobnost z\u00e1va\u017en\u00fdch malformac\u00ed nad b\u011b\u017enou \u00farove\u0148.<\/p>\n

    Mohu Psyquit n\u00e1hle vysadit?<\/h3>\n

    Lep\u0161\u00ed je d\u00e1vky postupn\u011b sni\u017eovat, zejm\u00e9na po dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed \u2014 n\u00e1hl\u00e9 vysazen\u00ed m\u016f\u017ee zp\u016fsobit abstinen\u010dn\u00ed dyskinezi, nespavost, nevolnost, pocen\u00ed a n\u00e1vrat psych\u00f3zy nebo m\u00e1nie. Sni\u017eujte d\u00e1vku o 25\u201350 mg ka\u017ed\u00fdch 1\u20132 t\u00fddny.<\/p>\n

    Jak se m\u00e1 Psyquit skladovat?<\/h3>\n

    Skladujte p\u0159i teplot\u011b 15\u201330 \u00b0C v p\u016fvodn\u00edm blistrov\u00e9m obalu, mimo dosah vlhkosti a slune\u010dn\u00edho sv\u011btla. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/p>\n

    Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce jsou ur\u010deny dosp\u011bl\u00fdm u\u017e\u00edvaj\u00edc\u00edm p\u0159edepsan\u00e9 psychiatrick\u00e9 l\u00e9ky a nenahrazuj\u00ed individu\u00e1ln\u00ed l\u00e9ka\u0159skou p\u00e9\u010di. Antidepresiva, antipsychotika a p\u0159\u00edbuzn\u00e9 l\u00e9ky mohou interagovat s jin\u00fdmi l\u00e9ky, alkoholem a st\u00e1vaj\u00edc\u00edmi zdravotn\u00edmi stavy. Jak\u00e9koli nov\u00e9 l\u00e9ky, zm\u011bnu d\u00e1vkov\u00e1n\u00ed nebo pl\u00e1novan\u00e9 vysazen\u00ed konzultujte s kvalifikovan\u00fdm l\u00e9ka\u0159em. Pokud se u v\u00e1s objev\u00ed sebevra\u017eedn\u00e9 my\u0161lenky, m\u00e1nie, t\u011b\u017ek\u00e1 akathisie, p\u0159\u00edznaky serotoninov\u00e9ho syndromu (vysok\u00e1 hore\u010dka, zmatenost, svalov\u00e1 ztuhlost, zrychlen\u00fd srde\u010dn\u00ed tep) nebo neuroleptick\u00fd malign\u00ed syndrom, vyhledejte okam\u017eit\u011b l\u00e9ka\u0159skou pomoc.<\/div>\n

    <\/p>\n

    Souvisej\u00edc\u00ed alternativy<\/h3>\n

    Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n